Prevalence of and risk factors for abnormal ophthalmological findings in children with a newly diagnosed brain tumor: a Dutch prospective nationwide cohort study.

Abstract

Purpose : Visual impairment is a serious adverse effect in children with a brain tumor. To date, visual impairment is often underestimated and unrecognized, while early detection of visual impairment is important to potentially preserve the visual function. Our aim was to assess the prevalence and type of abnormal ophthalmological findings in children with a newly diagnosed brain tumor and to identify potential oncological and clinical risk factors.

Methods : In this prospective nationwide cohort study, we included children, aged 0-18 years, with a newly diagnosed brain tumor in the Netherlands between May 2019 and August 2021. A comprehensive ophthalmological examination (including orthoptic evaluation, visual acuity, visual fields and fundoscopy) was performed at diagnosis. Multivariable logistic regression analyses were performed to estimate the odds ratio (OR) and 95% confidence interval (CI) of the risk factors.

Results : In total, 170 children were included (43.5% female; median age [interquartile range], 8.3 [3.9 – 13.0] years; 48.2% infratentorial tumors, 35.3% midline tumors and 16.5% cerebral hemispheres tumors). Overall, 101 children (59.4%) presented with visual symptoms at diagnosis. The most common findings on ophthalmological examination were papilledema (50.6%), gaze deficits (31.8%), visual field defects (29.4%), nystagmus (23.5%), strabismus (18.8%) and decreased visual acuity (10.5%). The risk of papilledema was associated with older age in years (OR 1.2, 95% CI 1.1 – 1.3) and hydrocephalus (OR 15.8, 95% CI 5.7 – 43.4). Visual field defects were detected more frequently in children with a tumor located in the cerebral hemisphere (OR 5.3, 95% CI 1.5 – 19.1) or midline (OR 6.0, 95% CI 2.0 - 18.1).

Conclusions : We found a high prevalence of abnormal ophthalmological findings in an unselected cohort of children at brain tumor diagnosis. These findings emphasize the need of standardized ophthalmological surveillance and of awareness of health care providers for ophthalmological abnormalities in this patient group.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.